Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 12/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23319935 | 0.89 | HAO1 (0.48) | HAO1PRKAG1PRKAA1PRKAB1HPGDS | |
| SCHEMBL21296970 | 0.87 | ALPL (0.42) | HAO1PRKAG1PRKAA1PRKAB1ALPL | |
| SCHEMBL31166215 | 0.85 | PIN1 (0.40) | HAO1HPGDS | |
| SCHEMBL23320005 | 0.85 | PIN1 (0.40) | HAO1HPGDS | |
| SCHEMBL23319930 | 0.84 | XDH (0.37) | HAO1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL23319968 | 0.84 | HAO1 (0.50) | HAO1PRKAG1PRKAA1PRKAB1ALPL | |
| SCHEMBL29968360 | 0.84 | HAO1 (0.50) | HAO1PRKAG1PRKAA1PRKAB1ALPL | |
| SCHEMBL21296847 | 0.84 | PRKAG1 (0.51) | HAO1PRKAG1PRKAA1PRKAB1ALPL | |
| SCHEMBL21296854 | 0.84 | HAO1 (0.44) | HAO1PRKAG1PRKAA1PRKAB1HPGDS | |
| SCHEMBL23319891 | 0.83 | METAP2 (0.39) | HAO1PRKAG1PRKAA1PRKAB1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112399873-B | Triazole glycolate oxidase inhibitors | 坎特罗治疗有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20210403439-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | VENTHERA, INC. | 2021-12-30 | — | — | US | disclosed |
| EP-3817816-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | Orfan Biotech Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-112399873-A | Triazole glycolate oxidase inhibitor | 奥凡生物科技公司 | 2021-02-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | XDH, DUOX1, PNPO | HAO1 6/4885PRKAG1 2945/4885PRKAA1 2067/4885 |
| US-20210403439-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | XDH, DUOX1, PNPO | HAO1 6/4885PRKAG1 2945/4885PRKAA1 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.